zacks.com · 26 jun

Abbott vs. DexCom: Which CGM Stock Is the Better Option Right Now?

DXCM outpaces Abbott with expanding CGM access, new product launches and broader coverage, making it the stronger stock to watch now.

zacks.com · 24 jun

DexCom to Roll Out Reimagined Stelo App With Global Expansion Plans

DXCM's redesigned Stelo app is set for a July U.S. rollout, with international expansion and pediatric clearance broadening its glucose insights push.

businesswire.com · 23 jun

Dexcom Further Advances Vision of Glucose Biosensing for All

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today announced at Aspen Ideas: Health a series of milestones that advance its vision of making glucose biosensing more accessible. Notably, the company announced pediatric clearance for the Stelo Glucose Biosensor and the launch of its fully reimagined Stelo app experience in July for Apple iPhone and Android users in the United States.“Glucose matters for everyone and better understanding it can h.

marketbeat.com · 20 jun

3 Non-Pharma Firms That Could Benefit From the GLP-1 Trend

The GLP-1 revolution is quietly continuing even as investor interest has moved on to more timely topics. One of the best ways to access the fast-growing weight loss drug space is via makers like Novo Nordisk NYSE: NVO or Eli Lilly NYSE: LLY, the leading companies responsible for developing and manufacturing products like Ozempic and Zepbound.

barrons.com · 18 jun

Living Longer Is Big Business. These Stocks Will Benefit.

TD Cowen analysts estimate that the total addressable market for longevity healthcare exceeds $250 billion.

marketbeat.com · 18 jun

3 Stocks Doing the Heavy Lifting in Healthcare's Rebound

Until recently, it had been a lackluster year for the healthcare sector. From high medical utilization squeezing insurers to structural cost pressures and valuation hangovers, medical stocks stocks have lagged much of the broader market this year.

forbes.com · 17 jun

The Healthcare M&A Wave

In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here.

zacks.com · 16 jun

DXCM Receives FDA Clearance for Stelo OTC CGM System for Children

DexCom's FDA-cleared Stelo OTC glucose biosensor now covers children aged above 2 years not using insulin, expanding access to smartphone-linked CGM insights.